Business Wire

CA-INGENIO

2.5.2022 19:15:06 CEST | Business Wire | Press release

Share
Stars Align for Merger Between US and European Online Wellness Giants, Ingenio and adviqo

Ingenio, LLC (“Ingenio”), a portfolio company of Alpine Investors, and the owner of North America’s largest online marketplace and media platform focused on spiritual and emotional wellness, has acquired its largest European peer, adviqo Group (“adviqo”).

The transaction creates the global leader in this fast-growing segment of the media and technology sector, combining Ingenio’s 12 brands, which include Keen.com, Purple Garden, Horoscope.com and Astrology.com, with adviqo’s 19 brands, which feature Questico, Horoskop.de, and Kang.

Since being founded, the two companies have facilitated over 180 million consultations between customers and advisors (counselors, coaches, guides and spiritualists).

Furthermore, Ingenio owns and operates one of the world’s largest astrology media companies. Its four media brands reach over 20 million people monthly. Meanwhile, adviqo reaches over 36 million households through its TV broadcasts, in addition to its digital platforms. The combined media businesses will offer customers the largest global collection of astrology content.

During the Covid-19 pandemic Ingenio saw a surge in users across its platforms, as people – and especially millennials – increasingly turned to technology to connect more meaningfully and conveniently. This was reflected in Ingenio’s customer base which grew 30% since the start of the pandemic. In anticipation of its strong growth prospects, Ingenio recently appointed Kirstin Hoefer as Keen.com’s first Brand President. She will be responsible for leading and driving top-line growth and product innovation.

Warren Heffelfinger, CEO of San Francisco-headquartered Ingenio, said: “This deal represents a major milestone in unlocking our next stage of growth. We will be stronger together as we explore opportunities to expand into new markets, drive innovation, and sharpen our focus on personal wellness.

“The combination of our leading businesses brings clear benefits to all stakeholders. As we pursue our joint vision of becoming the global leader in personal guidance, life advice and wellness, customers will see improved products and services provided by a broader, wellness-related product portfolio tailored to their needs. Our advisors will benefit from enhanced features and greater resource support, access to a broader consumer base, and accelerated revenue growth. Employees will also have access to more global career paths. Importantly, both companies are aligned around a mutual commitment to empower people to live happier lives.

“I’d like to thank all our employees for their hard work over many years to help us reach this point. We have exciting prospects ahead, along with stability of ownership and management, and we continue to attract new high-quality investors like Apollo, a blue-chip alternative asset manager.”

Bryan Leppi, Co-founder and Chief Business Development Officer for Berlin-based adviqo, added: “Ingenio and adviqo are leaders in our respective regions. With little geographical crossover we offer complementary product suites featuring online marketplaces, websites and apps, streaming media and podcasts, content-based online offers, as well as TV and magazines. So, together, we are creating a comprehensive and global market leader.

“While there is a strong business case for this combination, having shared values and attitudes, and the opportunity to learn from each other, is equally important for the longterm success of our combined group. This will allow us to tap into new products and markets and to further develop our skill sets like never before. We are excited about what the future holds.”

About Ingenio

Ingenio is the market leader in spiritual and emotional guidance in the US. Headquartered in San Francisco, CA, Ingenio is a collection of online destinations including Keen.com and Purple Garden, where people find emotional and spiritual guidance on love, relationships, and life. With a team of more than 140 colleagues, Ingenio is passionate about continuous improvement and connecting people with the best content and advisors to empower them to live happier lives.

Ingenio also owns and operates one of the world’s largest astrology media companies, with brands including Horoscope.com, Astrology.com, Horoscopo.com and SunSigns.com. They reach more than 20 million unique users each month and publish daily content via the four websites, 39 email newsletters, and three mobile apps.

About adviqo

adviqo is the market leader in spiritual and emotional guidance in Europe, with headquarters in Berlin, Germany. It employs more than 240 people worldwide, including Germany, France, Italy, Spain and the UK.

adviqo’s mission is to provide person-to-person advice and inspiring content to anyone searching for self-care, personal growth and clarity. Its portfolio includes websites and apps, streaming media and podcasts, content-based online offerings, TV and magazines. adviqo operates leading brands including Questico, The Circle, Kang, Horoskop.de, viversum and Zodiac Touch.

About Alpine Investors

Alpine Investors is a people-driven private equity firm that is committed to building enduring companies by working with, learning from, and developing exceptional people. Alpine specializes in investments in companies in the software and services industries. Its PeopleFirst strategy includes a CEO program that allows Alpine to bring leadership to situations where additional or new management is needed post-transaction. Alpine is currently investing out of its $2.25 billion eighth fund.

For more information, visit http://www.alpineinvestors.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye